Takeda's Zasocitinib Delivers in Phase 3 for Hard-to-Treat Psoriasis
Takeda calls phase 3 results for oral TYK2 inhibitor zasocitinib 'top-notch' in difficult-to-treat psoriasis, positioning a pill against biologics.
Topic
Zasocitinib
Topic
Zasocitinib
Zasocitinib Beats Deucravacitinib on Skin Clearance in Phase 3
Zasocitinib delivered superior skin clearance versus deucravacitinib in a Phase 3 head-to-head plaque psoriasis trial, raising th…
Zasocitinib Beats Deucravacitinib in Phase 3 Head-to-Head Psoriasis Trial
Phase 3 head-to-head data show once-daily zasocitinib achieved superior skin clearance versus deucravacitinib in plaque psoriasis…
Zasocitinib Beats Deucravacitinib Head-to-Head in Phase 3 Psoriasis
In the Phase 3 LATITUDE Atlas head-to-head trial, zasocitinib achieved PASI-100 in 36.5% of patients at Week 16 versus 13.9% for…
Takeda reports zasocitinib superior to deucravacitinib
Takeda says its investigational TYK2 inhibitor zasocitinib beat deucravacitinib on efficacy in a head-to-head claim that could re…
Zasocitinib Beats Deucravacitinib in Phase 3 Head-to-Head Trial
Zasocitinib showed superior efficacy versus deucravacitinib in Phase 3 head-to-head psoriasis data, with rapid, durable clearance…
Zasocitinib Clears Psoriasis at Hardest-to-Treat Sites in Once-Daily Pill
Once-daily oral TYK2 inhibitor zasocitinib cleared psoriasis at the scalp, palms, soles and nails — sites where topicals and curr…